A new PNAS study identifies a previously underappreciated Gq/11–PLC–PKC–NEDD4L pathway that marks CB1 receptors for proteasomal degradation. The findings help explain how repeated THC exposure can reduce receptor availability and contribute to cannabinoid tolerance.
Category: Pharmacology
Endocannabinoid System (ECS)
Read more
Paracetamol, 2-AG and CB1: The ECS Story Just Got More Complicated
New mouse research reveals that paracetamol’s pain-relieving effects depend on CB1 receptors and the enzymes DAGL and MAGL, while reshaping prostaglandin and wider lipid signalling.
Endocannabinoid System (ECS)
Read more
Liraglutide, 2‑AG and the Microbiome: A New Gut–Brain Pathway for Antidepressant Effects
From metabolic drug to mood modulator A new paper in Cell Host & Microbe has just delivered one of the most compelling mechanistic stories yet for how the endocannabinoid system (ECS) links metabolic drugs, the gut microbiome, and mood regulation. The study shows that the antidepressant effects of the GLP‑1…
Endocannabinoid System (ECS)
Read more
Paracetamol Confirmed as a Direct Analgesic DAGL Inhibitor: New Preprint Evidence
Important Note: This blog post discusses findings from a recent scientific preprint, meaning the research has not yet been formally peer-reviewed. Preprints allow for rapid dissemination of findings, but results should be interpreted cautiously until confirmed by peer-reviewed publication. Recently, we reported on a surprising new way that paracetamol (also known…
Pharmacology
Read more
Acetaminophen (APAP) & the ECS: A Surprising New Twist in How Tylenol Really Works
New research upends our understanding of how acetaminophen (paracetamol) provides pain relief via the endocannabinoid system. Discover how it directly inhibits DAGLα, reducing 2-AG levels – a surprising twist on conventional ECS wisdom. Explore the implications for future drug development.